FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072429445> ?p ?o ?g. }

• W2072429445 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCIntroduction: Signal transduction in the Ras-Raf-MEK-ERK (MAPK) pathway plays a key role in cell survival, growth and proliferation. The pathway is controlled by extracellular signals through receptor tyrosine kinases (RTK) and is activated by oncogenic mutations in many types of cancer. The B-Raf mutants are found in various cancers, such as melanoma, colorectal, ovarian, and prostate cancer. The Ras mutants are also found in various carcinomas including colon cancer, pancreatic cancer, non-small-cell lung cancer, and liver cancer. The mutated K-Ras gene sends continuous signals to the colorectal cancer cells, telling them to grow independent of the way ERBITUX blocks the EGFR growth signals. Especially, over 90% of detected mutations in B-Raf are a V600E which leads to constitutive kinase activity 500-fold greater than B-Raf wild type and correlates with increased malignancy. Vascular endothelial growth factor (VEGF) and its receptors have been implicated in the angiogenesis that is essential for growth and metastasis of solid tumors. Since formation of solid tumors are angiogenesis dependent, several strategies have been developed to inhibit VEGF signal transduction as part of anticancer therapy. The first VEGFR2 and Raf-1 inhibitor to enter clinical development was the multikinase inhibitor SORAFENIB, which is now approved for the treatment of patients with advanced renal cell carcinoma. More potent dual inhibitors against VEGFR2 and Raf-1 may be beneficial for patients suffering from various tumors. In this study, some of rational-designed compounds were synthesized and carried out the in vitro and in vivo studies to find more efficient VEGFR2 and Raf-1 inhibitors.Methods: About two hundreds of compounds were designed and synthesized. in vitro assays and in vivo studies were performed to characterize the potential of VEGFR2 and Raf-1 inhibitors for solid tumors.Results: Compound UI-162 showed strong kinase inhibition against VEGFR2 (12 nM), B-Raf V600E mutant (0.2 nM), B-Raf wildtype (2.0 nM) and Raf-1(0.6 nM). The compound showed good inhibitory effect in against malignant cells expressing K-Ras or B-Raf V600E mutant type of cell-line (SK-MEL-2 GI50: 133 nM / HCT-116 GI50: 229 nM / MDA-MB231 GI50: 278 nM / A375P GI50: 51 nM / HT29 GI50: 40 nM / COLO 205 GI50: 12 nM, respectively). In mechanism studies, the phosphorylation of MEK and ERK were suppressed by the UI-162 compound in HCT-116 cell-line. In addition, paradoxical effects were not detected compared with VEMURAFENIB. The compound had also a good anti-proliferative activity against HUVEC and showed a good oral bioavailability.Conclusions: The results of in vitro and in vivo studies suggests that dual inhibition of VEGFR2 and Raf-1 may provide strong antitumor efficacy and that UI-162 is a promising candidate for the treatment of various human cancers harboring the K-Ras and B-Raf V600E mutation.Citation Format: Seung Yong Kim, Younho Lee, Hyungtae Bang, Kihwan Eum, Sungpyo Hong, Ky-Youb Nam, Nam Song Choi, Ju Hee Kang, Hara Kang, Kil Won Kim, Michael Lee, Soon Kil Ahn. Discovery of novel VEGFR2 and Raf-1 kinase inhibitorsuppressing MAPK signaling pathway in K-Ras mutant cancer cell-lines. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 941. doi:10.1158/1538-7445.AM2013-941" @default.
• W2072429445 created "2016-06-24" @default.
• W2072429445 creator A5004975261 @default.
• W2072429445 creator A5007851185 @default.
• W2072429445 creator A5028796996 @default.
• W2072429445 creator A5035190500 @default.
• W2072429445 creator A5036955413 @default.
• W2072429445 creator A5038254602 @default.
• W2072429445 creator A5039019636 @default.
• W2072429445 creator A5063605233 @default.
• W2072429445 creator A5069667659 @default.
• W2072429445 creator A5071359370 @default.
• W2072429445 creator A5078983798 @default.
• W2072429445 creator A5091849510 @default.
• W2072429445 date "2013-04-15" @default.
• W2072429445 modified "2023-09-25" @default.
• W2072429445 title "Abstract 941: Discovery of novel VEGFR2 and Raf-1 kinase inhibitorsuppressing MAPK signaling pathway in K-Ras mutant cancer cell-lines." @default.
• W2072429445 doi "https://doi.org/10.1158/1538-7445.am2013-941" @default.
• W2072429445 hasPublicationYear "2013" @default.
• W2072429445 type Work @default.
• W2072429445 sameAs 2072429445 @default.
• W2072429445 citedByCount "0" @default.
• W2072429445 crossrefType "proceedings-article" @default.
• W2072429445 hasAuthorship W2072429445A5004975261 @default.
• W2072429445 hasAuthorship W2072429445A5007851185 @default.
• W2072429445 hasAuthorship W2072429445A5028796996 @default.
• W2072429445 hasAuthorship W2072429445A5035190500 @default.
• W2072429445 hasAuthorship W2072429445A5036955413 @default.
• W2072429445 hasAuthorship W2072429445A5038254602 @default.
• W2072429445 hasAuthorship W2072429445A5039019636 @default.
• W2072429445 hasAuthorship W2072429445A5063605233 @default.
• W2072429445 hasAuthorship W2072429445A5069667659 @default.
• W2072429445 hasAuthorship W2072429445A5071359370 @default.
• W2072429445 hasAuthorship W2072429445A5078983798 @default.
• W2072429445 hasAuthorship W2072429445A5091849510 @default.
• W2072429445 hasConcept C101544691 @default.
• W2072429445 hasConcept C104317684 @default.
• W2072429445 hasConcept C121608353 @default.
• W2072429445 hasConcept C126322002 @default.
• W2072429445 hasConcept C143065580 @default.
• W2072429445 hasConcept C167734588 @default.
• W2072429445 hasConcept C170493617 @default.
• W2072429445 hasConcept C184235292 @default.
• W2072429445 hasConcept C2776470698 @default.
• W2072429445 hasConcept C2777025900 @default.
• W2072429445 hasConcept C2778019345 @default.
• W2072429445 hasConcept C2778695046 @default.
• W2072429445 hasConcept C2779013556 @default.
• W2072429445 hasConcept C2780394083 @default.
• W2072429445 hasConcept C2781249067 @default.
• W2072429445 hasConcept C502942594 @default.
• W2072429445 hasConcept C526805850 @default.
• W2072429445 hasConcept C55493867 @default.
• W2072429445 hasConcept C57074206 @default.
• W2072429445 hasConcept C62478195 @default.
• W2072429445 hasConcept C71924100 @default.
• W2072429445 hasConcept C86803240 @default.
• W2072429445 hasConcept C95444343 @default.
• W2072429445 hasConcept C96232424 @default.
• W2072429445 hasConceptScore W2072429445C101544691 @default.
• W2072429445 hasConceptScore W2072429445C104317684 @default.
• W2072429445 hasConceptScore W2072429445C121608353 @default.
• W2072429445 hasConceptScore W2072429445C126322002 @default.
• W2072429445 hasConceptScore W2072429445C143065580 @default.
• W2072429445 hasConceptScore W2072429445C167734588 @default.
• W2072429445 hasConceptScore W2072429445C170493617 @default.
• W2072429445 hasConceptScore W2072429445C184235292 @default.
• W2072429445 hasConceptScore W2072429445C2776470698 @default.
• W2072429445 hasConceptScore W2072429445C2777025900 @default.
• W2072429445 hasConceptScore W2072429445C2778019345 @default.
• W2072429445 hasConceptScore W2072429445C2778695046 @default.
• W2072429445 hasConceptScore W2072429445C2779013556 @default.
• W2072429445 hasConceptScore W2072429445C2780394083 @default.
• W2072429445 hasConceptScore W2072429445C2781249067 @default.
• W2072429445 hasConceptScore W2072429445C502942594 @default.
• W2072429445 hasConceptScore W2072429445C526805850 @default.
• W2072429445 hasConceptScore W2072429445C55493867 @default.
• W2072429445 hasConceptScore W2072429445C57074206 @default.
• W2072429445 hasConceptScore W2072429445C62478195 @default.
• W2072429445 hasConceptScore W2072429445C71924100 @default.
• W2072429445 hasConceptScore W2072429445C86803240 @default.
• W2072429445 hasConceptScore W2072429445C95444343 @default.
• W2072429445 hasConceptScore W2072429445C96232424 @default.
• W2072429445 hasLocation W20724294451 @default.
• W2072429445 hasOpenAccess W2072429445 @default.
• W2072429445 hasPrimaryLocation W20724294451 @default.
• W2072429445 hasRelatedWork W1575387834 @default.
• W2072429445 hasRelatedWork W1639844185 @default.
• W2072429445 hasRelatedWork W1926130650 @default.
• W2072429445 hasRelatedWork W1996349796 @default.
• W2072429445 hasRelatedWork W2041062963 @default.
• W2072429445 hasRelatedWork W2054460207 @default.
• W2072429445 hasRelatedWork W2055670485 @default.
• W2072429445 hasRelatedWork W2069032357 @default.
• W2072429445 hasRelatedWork W2077914269 @default.
• W2072429445 hasRelatedWork W2090143268 @default.
• W2072429445 hasRelatedWork W2124622004 @default.
• W2072429445 hasRelatedWork W2146350056 @default.
• W2072429445 hasRelatedWork W2205509090 @default.
• W2072429445 hasRelatedWork W2289311855 @default.

• next